View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 22, 2020updated 23 Apr 2020 8:19am

Study finds hydroxychloroquine to have no benefit in Covid-19

By Allie Nawrat

A study carried out by researchers in the US has found that hydroxychloroquine, an antimalarial President Trump has described as a ‘game changer’ in the fight against Covid-19, showed no benefit against the novel coronavirus and did not reduce the risk of mechanical ventilation.

Also, the trial over more than 300 patients at US Veterans Health Administration medical centres found that the drug was associated “with an increased overall mortality rate”; 27.8% of the 97 patients who received hydroxychloroquine died, compared to 11.8% of the 158 patients in the control group.

The study is yet to be peer-reviewed, but the results have been submitted to the New England Journal of Medicine. The research was funded by the National Institutes of Health and the University of Virginia.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU